SLG
AUPH icon

Stanley-Laman Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Stanley-Laman Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-48,994
Closed -$276K – 222
2018
Q2 		$276K Buy
+48,994
New +$273K 0.06% 239

Other funds holding AUPH

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Stanley-Laman Group's AUPH Position: Q3 2018 in Review

Stanley-Laman Group sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2018, closing a stake of 48,994 shares — an estimated $276K sold.

Stanley-Laman Group first reported a position in AUPH in Q2 2018 and held it in 1 quarter. The position peaked at $276K in Q2 2018. 64 funds tracked by Wall St. Rank hold AUPH as of Q3 2018.

  • Stanley-Laman Group reported no remaining Aurinia Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 48,994 Aurinia Pharmaceuticals shares in Q3 2018, an estimated $276K.
  • Stanley-Laman Group first reported a position in Aurinia Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Stanley-Laman Group's Aurinia Pharmaceuticals position peaked at $276K in Q2 2018.
  • 64 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2018.

Based on Stanley-Laman Group's 13F filing for Q3 2018, filed 30 Oct 2018.